MS-N154 · Nutrition supplement · Cachexia · Mixed and negative randomized evidence · Appraised 27 October 2026

Does the defined HMB/arginine/glutamine mixture preserve lean body mass or improve function in cancer cachexia?

Evidence at a glance

• Evidence label: Early positive signal not confirmed in larger or lung-cancer trials
• Benefit: A small early trial reported lean-mass gain, but a 472-person phase III trial found no significant primary or secondary benefit, and NOURISH found no benefit in advanced lung cancer.
• Certainty: Low to moderate that the mixture does not reliably improve outcomes; high attrition and adherence problems limit the trials.
• Risk: No serious adverse events were reported in NOURISH, but the large amino-acid load requires review in kidney, liver and metabolic disease.

What was studied

The formulation generally provided HMB 3 g/day, arginine 14 g/day and glutamine 14 g/day. A 2002 double-blind trial reported 32 evaluable participants at four weeks. RTOG 0122 randomized 472 advanced-cancer patients for eight weeks. NOURISH randomized 38 people with advanced lung cancer, 19 per arm, alongside structured nutrition, exercise and symptom support.

What the evidence found

The early trial reported a 1.12 kg fat-free-mass gain versus a 1.34 kg loss at four weeks (P=0.02). RTOG 0122 found no significant intention-to-treat difference in lean mass, weight, fatigue or quality of life; only 37% completed treatment. NOURISH stopped early for slow accrual and poor adherence: treatment success was 16% versus 47% in controls, with no benefit in lean mass, strength or quality of life.

How to interpret it

The largest and most clinically relevant trials do not support a reliable benefit. The new pancreatic-cancer registry NCT07883161 is an ongoing pilot; registration is not efficacy evidence.

Practical safety context

Cancer cachexia needs evaluation for reversible contributors, symptom control and dietitian support. Kidney dysfunction, hepatic disease, electrolyte problems and medication interactions should be reviewed before concentrated amino-acid mixtures.

Questions for the care team

• Is the weight loss due to cachexia, inadequate intake, obstruction, malabsorption or another treatable cause?
• Does the proposed product match the studied 3/14/14-g formulation?
• What outcome—weight, lean mass, strength or quality of life—will be monitored?

Funding and conflicts

Funding varied by trial; NOURISH reported National Cancer Research Institute support and no serious adverse events. Product-specific conflicts and manufacturer involvement should be checked before extrapolating.

Sources

• Early randomized trial (PMID 11975938)
• RTOG 0122 phase III trial (PMID 18293016)
• NOURISH trial (PMID 34247580)
• NOURISH full text
• Ongoing pancreatic-cancer pilot NCT07883161

Last literature search: 27 October 2026. Record appraisal: 27 October 2026. This page is educational and does not replace individualized medical advice. Symptom, biomarker, immune-marker or nutritional changes must not be interpreted as proof of tumor control, recurrence prevention or longer survival unless those outcomes were directly tested.